BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

4-Antibody AG Meets First Milestone in Boehringer Ingelheim Corporation Collaboration


4/19/2011 9:43:47 AM

Basel, Switzerland, April 19th, 2011: 4-Antibody AG today announced that the Company has achieved the successful completion of a first milestone in its ongoing collaboration with Boehringer Ingelheim.

4-Antibody’s first R&D collaboration with a major pharma partner, Boehringer Ingelheim, commenced in early 2010 and is a long-term collaboration to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. The collaboration centres on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid antibody discovery and also incorporates the novel, rapid, in vivo Hu-PAC® technology for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim.

Robert Burns, 4-Antibody’s CEO, said:

“Long-term collaborations serve an important role in validating technology platforms and so we’re delighted to announce that we’ve successfully delivered on the first major milestone in this key multi-target collaboration. I’d expect this to add further momentum to our other ongoing partnering activities.”

About 4-Antibody AG

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in-vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating full-length IgG format human antibody libraries expressed in mammalian B cells (the cell designed by nature for optimal antibody display). This in vitro process is supported by the in vivo HU-PAC® filter used to select only those antibody product candidates with the most desirable drug characteristics. 4-Antibody provides access to its technologies to select pharmaceutical R&D collaborators and is also generating an in-house pipeline of antibody drugs. The Company’s lead development product is an anti-cytomegalovirus antibody drug. 4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, Switzerland and Jena, Germany. For more information please visit: www.4-antibody.com

Further Information:

Dr Robert Burns

CEO

4-Antibody AG

t: +41 61 697 1351

e: robert.burns@4-antibody.com

Dr Douglas Pretsell

Associate Partner

College Hill

t: +44 20 7866 7868

e: douglas.pretsell@collegehill.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->